Challenges in Current Regenerative Medicine Approaches:
Today, more than 90% of the Down Syndrome (DS) population receive an Alzheimer's diagnosis in their lifetime.
1.While DS is not a rare disease, “Acute Regression with DS”, typically ages from 20s to 50s, is a rare disease so we will develop as an orphan drug
2.A rare disease= low cost and fast development = early exit!
3.DS is a human model of AD- Extra Amyloid Precursor Protein (APP) in Chromosome 21.
Our pre-clinical studies have revealed a remarkable breakthrough: our technology has demonstrated the ability to significantly augment the population of stem cells and promote neurogenesis.
studies conducted on
5xFAD mice: Transgenic Alzheimer model mice
Empowering Stem Cell Proliferation: Our Drug, APC-100, Reveals Remarkable Results in Boosting Neural and Mesenchymal Stem Cell Activity
These findings represent a significant leap forward in our quest to unlock the full potential of stem cells and promote neurogenesis. The promising results achieved through the combination of KS217 and phenserine (our drug APC-100) pave the way for future advancements in the treatment of neurodegenerative conditions.
We remain committed to further exploring the vast possibilities of KS217 and its potential impact on neuroregeneration and cognitive enhancement.
With these groundbreaking outcomes, we are hopeful that our research will lead to transformative therapies that address the needs of individuals affected by cognitive decline and neurodegenerative disorders.
Studies conducted on
5xFAD mice: Transgenic Alzheimer model mice
At Progenicyte, we are harnessing the power of our groundbreaking innovative technology—a small molecular weight compound—to pave the way for bringing a significant increase in endogenous stem cells to the forefront of clinical applications.
Our pioneering technology offers a transformative approach in the treatment of neurodegenerative diseases. By utilizing orally administered drugs, we have successfully developed a method to activate and enhance the existing neural stem cells within the brain throughout an individual's lifespan.
In addition to its oral administration capabilities, our pioneering technology exhibits remarkable versatility when applied topically. By harnessing the power of specifically formulated drugs, we have unlocked a range of exciting applications that can address various concerns.
With these remarkable applications, our technology represents a paradigm shift in addressing age-related concerns, hair loss, and ocular health. Through topically administered drugs, we strive to provide effective and accessible solutions that enhance well-being and rejuvenate various aspects of human health.
We are dedicated to advancing the clinical development of a groundbreaking small molecule compound that holds immense potential for augmenting endogenous stem cells. This pioneering compound was initially conceived by the esteemed neuroscience expert, Dr. Kiminobu Sugaya, and his exceptional research team.
Progenicyte Therapeutics, Inc.
Copyright © 2024 Progenicyte Therapeutics, Inc. - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.